Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;8(5):1073-1085.
doi: 10.1002/acn3.51350. Epub 2021 Mar 30.

Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers"

Edith L Graham  1 , Jeffrey R Clark  1 , Zachary S Orban  1 , Patrick H Lim  1 , April L Szymanski  1 , Carolyn Taylor  1 , Rebecca M DiBiase  1 , Dan Tong Jia  1 , Roumen Balabanov  1 , Sam U Ho  1 , Ayush Batra  1 , Eric M Liotta  1 , Igor J Koralnik  1
Affiliations

Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers"

Edith L Graham et al. Ann Clin Transl Neurol. 2021 May.

Abstract

Objective: Most SARS-CoV-2-infected individuals never require hospitalization. However, some develop prolonged symptoms. We sought to characterize the spectrum of neurologic manifestations in non-hospitalized Covid-19 "long haulers".

Methods: This is a prospective study of the first 100 consecutive patients (50 SARS-CoV-2 laboratory-positive (SARS-CoV-2+ ) and 50 laboratory-negative (SARS-CoV-2- ) individuals) presenting to our Neuro-Covid-19 clinic between May and November 2020. Due to early pandemic testing limitations, patients were included if they met Infectious Diseases Society of America symptoms of Covid-19, were never hospitalized for pneumonia or hypoxemia, and had neurologic symptoms lasting over 6 weeks. We recorded the frequency of neurologic symptoms and analyzed patient-reported quality of life measures and standardized cognitive assessments.

Results: Mean age was 43.2 ± 11.3 years, 70% were female, and 48% were evaluated in televisits. The most frequent comorbidities were depression/anxiety (42%) and autoimmune disease (16%). The main neurologic manifestations were: "brain fog" (81%), headache (68%), numbness/tingling (60%), dysgeusia (59%), anosmia (55%), and myalgias (55%), with only anosmia being more frequent in SARS-CoV-2+ than SARS-CoV-2- patients (37/50 [74%] vs. 18/50 [36%]; p < 0.001). Moreover, 85% also experienced fatigue. There was no correlation between time from disease onset and subjective impression of recovery. Both groups exhibited impaired quality of life in cognitive and fatigue domains. SARS-CoV-2+ patients performed worse in attention and working memory cognitive tasks compared to a demographic-matched US population (T-score 41.5 [37, 48.25] and 43 [37.5, 48.75], respectively; both p < 0.01).

Interpretation: Non-hospitalized Covid-19 "long haulers" experience prominent and persistent "brain fog" and fatigue that affect their cognition and quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest pertaining to this publication.

Figures

Figure 1
Figure 1
Patient‐reported outcomes measurement information system (PROMIS®) quality of life and NIH Toolbox cognitive assessments demographic‐matched T‐scores in SARS‐CoV‐2+ (circles) and SARS‐CoV‐2‐ (squares) individuals. A T‐score of 50 is the mean/median for the demographic‐matched United States normative population with a standard deviation of 10. (A) PROMIS® cognitive function (C, filled symbols) and fatigue (F, empty symbols) assessments. Lower cognition scores indicate worse cognition quality of life and higher fatigue scores correspond to worse fatigue quality of life. Patient group median values are represented by horizontal bars. (B) NIH Toolbox assessments for processing speed (PS), attention (A), executive function (EF), and working memory (WM). Median values are represented by horizontal bars. One‐sample Wilcoxon signed‐rank test p‐values between patient group T‐scores and the demographic‐matched normative US population median of 50 are provided in the figure table.
Figure 2
Figure 2
Subjective impression of recovery compared to pre‐Covid‐19 baseline for SARS‐CoV‐2+ (A) and SARS‐CoV‐2‐ individuals (B). The patients were asked to grade their recovery at the time of their visit, assuming a pre‐Covid‐19 baseline of 100%. Each person is represented by a single time point, and r values demonstrate no meaningful relationship between time from onset and percentage of recovery.
See this image and copyright information in PMC

Similar articles

  • Evolution of neurologic symptoms in non-hospitalized COVID-19 "long haulers".
    Ali ST, Kang AK, Patel TR, Clark JR, Perez-Giraldo GS, Orban ZS, Lim PH, Jimenez M, Graham EL, Batra A, Liotta EM, Koralnik IJ. Ali ST, et al. Ann Clin Transl Neurol. 2022 Jul;9(7):950-961. doi: 10.1002/acn3.51570. Epub 2022 May 24. Ann Clin Transl Neurol. 2022. PMID: 35607826 Free PMC article.
  • Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity.
    Perez Giraldo GS, Ali ST, Kang AK, Patel TR, Budhiraja S, Gaelen JI, Lank GK, Clark JR, Mukherjee S, Singer T, Venkatesh A, Orban ZS, Lim PH, Jimenez M, Miller J, Taylor C, Szymanski AL, Scarpelli J, Graham EL, Balabanov RD, Barcelo BE, Cahan JG, Ruckman K, Shepard AG, Slutzky MW, LaFaver K, Kumthekar PU, Shetty NK, Carroll KS, Ho SU, Lukas RV, Batra A, Liotta EM, Koralnik IJ. Perez Giraldo GS, et al. Ann Neurol. 2023 Jul;94(1):146-159. doi: 10.1002/ana.26649. Epub 2023 Apr 19. Ann Neurol. 2023. PMID: 36966460 Free PMC article.
  • Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.
    Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, Suen J, Robba C, Fraser J, Cho SM. Premraj L, et al. J Neurol Sci. 2022 Mar 15;434:120162. doi: 10.1016/j.jns.2022.120162. Epub 2022 Jan 29. J Neurol Sci. 2022. PMID: 35121209 Free PMC article. Review.
  • Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms.
    Shanley JE, Valenciano AF, Timmons G, Miner AE, Kakarla V, Rempe T, Yang JH, Gooding A, Norman MA, Banks SJ, Ritter ML, Ellis RJ, Horton L, Graves JS. Shanley JE, et al. Ann Clin Transl Neurol. 2022 Jul;9(7):995-1010. doi: 10.1002/acn3.51578. Epub 2022 Jun 15. Ann Clin Transl Neurol. 2022. PMID: 35702954 Free PMC article.
  • Neurological Sequelae of COVID-19.
    Ahmad SJ, Feigen CM, Vazquez JP, Kobets AJ, Altschul DJ. Ahmad SJ, et al. J Integr Neurosci. 2022 Apr 6;21(3):77. doi: 10.31083/j.jin2103077. J Integr Neurosci. 2022. PMID: 35633158 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. COVID‐19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University and Medicine. JHU.edu: Johns Hopkins University & Medicine; 2021; Available from: https://coronavirus.jhu.edu/map.html.
    1. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID‐19. Lancet Neurol 2020;19(9):767–783. - PMC - PubMed
    1. Koralnik IJ, Tyler KL. COVID‐19: A global threat to the nervous system. Ann Neurol 2020;88(1):1–11. - PMC - PubMed
    1. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID‐19. JAMA 2020;324(6):603–605. - PMC - PubMed
    1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683–690. - PMC - PubMed

MeSH terms